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Abstract
Background: The exudative age-related macular degeneration (AMD) causes considerable healthcare costs for
patients and healthcare system, which are expected to grow as the population ages. The objective of this study
was to assess the incremental economic burden of exudative AMD by comparing total healthcare costs between
the exudative AMD group and non-AMD group to understand economic burden related to exudative AMD.
Methods: This retrospective cohort study used the National Health Insurance Service database including the entire
Korean population. Exudative AMD group included individuals with at least one claim for ranibizumab and one claim
using the registration code for exudative AMD (V201). Non-AMD group was defined as individuals without any claims
regarding the diagnostic code of H35.3 or ranibizumab. The exudative AMD group and non-AMD group were matched
using a propensity-score model. Incremental healthcare resource utilization and healthcare costs were measured during
a one-year follow-up by employing econometric models: ordinary least squares (OLS) with log transformation and
heteroscedastic retransformation; and generalized linear model (GLM) with a log link function and gamma distribution.
Results: A total of 7119 exudative AMD patients were matched to 7119 non-AMD patients. The number of outpatient
visits was higher in the exudative AMD group (P-value < 0.0001), while the length of hospitalization was shorter in
exudative AMD group (P-value < 0.0001). Exudative AMD patients had total costs 2.13 times (95%CI, 2.08–2.17) greater
than non-AMD group using OLS, and total costs 4.06 times (95%CI, 3.82–4.31) greater than non-AMD group using GLM.
Annual incremental total costs were estimated as $5519 (OLS) and $3699 (GLM).
Conclusions: Exudative AMD was associated with significantly increased healthcare costs compared to the non-AMD
group. Attention is needed to manage the socioeconomic burden of exudative AMD.
Keywords: Age-related macular degeneration, Cost of illness, Exudative AMD, Incremental cost, Macular degeneration,
Models, econometric, Ranibizumab, Propensity score
Background
Age-related macular degeneration (AMD) is a major
cause of irreversible visual loss in the elderly, and can be
classified as nonexudative or exudative [1]. The major
risk factor for AMD is old age, and generally a progres-
sive and irreversible visual loss occurs after the develop-
ment of exudative AMD [2, 3]. Visual loss is related with
substantially decreased quality of life that is comparable
to that of severe systemic diseases such as cancer, stroke,
and diabetes mellitus [4].
Early intervention with anti-vascular endothelial
growth factor (VEGF) therapy can reduce visual loss in
patients with exudative AMD, whereas it causes consid-
erable healthcare costs for patients and healthcare
system due to its high price and needs for repetitive
administration accompanied by frequent outpatient visits
[2, 5]. To ease the economic burden of patients with
AMD, the Korean registration program for rare intract-
able diseases provides copayment reduction. Given that
the prevalence of exudative AMD was reported to be
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0.36–0.60% in 2008–2014 in Korea and the prevalence is
continuously increasing as the population ages, the eco-
nomic burden of exudative AMD is also expected to
grow for both the individual patient and society [6–8].
However, there is a paucity of data exploring economic
burden of exudative AMD. A prospective, cross-sectional
study conducted in Canada, France, Germany, Spain, and
the UK estimated the annual societal cost per patient to
be €5300–12,445 in 2005 [9]. Among the UK cohort in
this five-country cross-sectional study, the annual health-
care costs of patients with exudative AMD was more than
seven times greater than that of non-AMD subjects [10].
In Korea, the annual cost of anti-VEGF therapy per
patient has increased from $7947 in 2010 to $10,246 in
2014, and the total burden of anti-VEGF therapy in
Korean population was expected to continue to increase
by the year 2030 [7]. Those studies are limited by several
factors, such as the absence of appropriate controls com-
parable to patients with exudative AMD in demographic
and clinical characteristics, possibilities of recall bias
resulting from the telephone survey, and a narrow defin-
ition of economic burden confined to the treatment costs
for exudative AMD. Within the limited budget, efficient
allocation of healthcare resources is crucial for sustainabil-
ity of healthcare system. Burden of disease can be used as
an evidence for priority in healthcare policies.
Therefore, we aimed to compare the incremental bur-
den, which encompasses all aspects of medical expenses,
in the exudative AMD group and non-AMD reference
group, whose set of comorbidities is similar to the ex-
udative AMD group, by using a nationwide claims data-
base covering the entire Korean population.
Methods
Study design and data source
We conducted a retrospective cohort study using data
from the National Health Insurance Service (NHIS)
database from 2006 through 2013, which was the total
period of available dataset. The NHIS database includes
records for the entire Korean population, since a single
payer program covers the entire Korean population,
about 50 million persons, through either the National
Health Insurance system (97%) or Medical Aid (3%)
[11]. Therefore, the NHIS database contains all medical
records related to medical claims made in Korea. We an-
alyzed 2 different NHIS datasets simultaneously in the
present study: the NHIS–customized database, which
consists of all patients with AMD extracted from the
whole NHIS database covering the entire Korean popu-
lation, and the NHIS–National Sample Cohort (NSC)
database, which consists of a validated and representa-
tive sample of 1,025,340 Korean residents (approxi-
mately 2.2% of Korean population) [12]. As the NHIS
did not allow us to access the whole database to set the
non-AMD population, we used the NHIS-NSC database
instead. Both datasets were built by NHIS, and only au-
thorized researchers were able to visit the analysis center
and access an onsite server for the purpose of analysis.
Study population
The provided NHIS-customized database consisted of all
patients with degeneration of macula having diagnostic
code of H35.3 among the entire Korean population. Of
these, we defined patients with incident exudative AMD
when individuals with at least one claim for ranibizumab
and one claim using the registration code for exudative
AMD (V201) between August 1, 2010 and December 31,
2012. Korean registration program for rare intractable
diseases was initiated in 2006 and covers 138 rare in-
tractable diseases including exudative AMD for copay-
ment reduction (up to 10%). To be registered for
copayment reduction, ophthalmologist should confirm
the diagnosis of exudative AMD according to the NHIS
diagnostic criteria as follows: (1) a dilated fundus exam-
ination using indirect ophthalmoscopy, (2) optical coher-
ence tomography, and (3) fluorescein angiography to
confirm the exudative AMD-related macular pathologic
features. The NHIS reviews the eligibility at the first
registration and verifies the accuracy and reliability of
the exudative AMD diagnosis based on the test results
described above and doctor’s note. After registration, all
exudative AMD-related claims contain the registration
code V201 in addition to the diagnostic code for exuda-
tive AMD. Detailed information was reported elsewhere
[6]. As the NHIS scheme covers only single anti-VEGF
agent during the study period, ranibizumab since August
2009 (aflibercept has been covered since November
2014), we included only ranibizumab in the analysis.
The first date of the claim for ranibizumab was desig-
nated as the index date. The index date had to precede
the first time a claim was made with registration code
V201 or be with 90 days of the first claim with registra-
tion code V201. In order to identify patients with inci-
dent exudative AMD, individuals were excluded if they
had any claims with ranibizumab or a registration code
V201 between January 1, 2006 and July 31, 2010.
We set the non-AMD group using the NHIS-NSC data-
base. The non-AMD group was defined as individuals
without any claims regarding the diagnostic code of H35.3
(‘degeneration of macula and posterior pole’), which in-
cludes H35.30 (‘nonexudative AMD’) and H35.31 (‘exuda-
tive AMD’) or regarding ranibizumab during the whole
study period.
Of these individuals in the both groups, we excluded
individuals having a history or new diagnosis of malig-
nant neoplasms (diagnostic codes of C00-C97) and
stroke (hospitalization with diagnostic codes of I60–I64)
during the entire study period, because these diseases
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generally involve enormous costs that can affect the
healthcare costs of exudative AMD [13].
Matching non-AMD group to the exudative AMD group
based on propensity scores
We preliminarily selected 10 to 20 matching-candidates
as the non-AMD group to each exudative AMD patient
according to their age group. Each of the matching-
candidates had to visit a healthcare facility on the same
date with the index date of matched-exudative AMD pa-
tient. We assigned the same index dates to these
matching-candidates as their matched-exudative AMD
patient. Then, we computed the propensity scores in the
exudative AMD group and their matching-candidates
using a logistic regression model and included the fol-
lowing covariates: the index date; age group, sex, type of
insurance, income level, residence and disability at the
index date; Charlson Comorbidity Index (CCI) score, co-
morbidities (i.e. myocardial infarction, congestive heart
failure, and dementia), length of hospitalization, number
of outpatient visits and number of emergency depart-
ment visits during the 1 year before the index date.
Square and interaction terms were also included. To cal-
culate CCI score, all diagnostic codes during the 1 year
before the index date were analyzed according to the
Quan’s coding algorithms [14]. Thereafter, we selected 1
non-AMD individual among matching-candidates to
each exudative AMD patient using estimated propensity
scores. The propensity score model was regarded as being
correctly specified if the baseline covariates were well-
balanced between the exudative AMD and non-AMD
groups in terms of standardized differences (< 10%) and
P-values (≥0.05), which measure the differences between
summary statistics of baseline covariates among two
groups [15, 16]. The discriminatory power of the propen-
sity score model was measured as a c-statistic.
Outcome measures
The exudative AMD and non-AMD groups were
followed for 1 year to measure healthcare resource
utilization and healthcare costs. Annual healthcare re-
source utilization per patient was assessed including the
total length of hospitalization, number of hospitaliza-
tions, number of outpatient visits, and number of emer-
gency department visits. From the perspective of Korean
payer, healthcare costs incorporated direct medical costs
incurred by both the insurer and the patient. Using a
gross-costing approach, annual healthcare cost per pa-
tient was calculated as the sum of all expenses incurred
during the period from 3 months before the index date
to 1 year after the index date. This analysis began 3
months prior to the index date so as to include pre-
diagnosis costs, which occur with regard to a diagnosis
of exudative AMD (e.g. retina fundus photo and fundus
fluorescein angiography, which are essential in the diag-
nosis of exudative AMD). Healthcare costs included all
expenses identifiable in healthcare claims, such as out-
patient visit, hospitalization, medication, medical devices,
and laboratory test. We categorized healthcare costs into
pre-diagnosis costs, AMD-related costs, ophthalmology
costs, and non-ophthalmology costs. The total burden of
exudative AMD for the Korean population was calcu-
lated according to the following formula:
Total burden of exudative AMD
¼ annual healthcare cost per patientð Þ
 projected number of Korean patients with exudative AMD in 2014ð Þ
We projected the number of Korean patients with ex-
udative AMD in 2014 using the direct standardization
method based on the 2008–2012 Korean data estimated
in the epidemiologic study for exudative AMD in Korea
and the information of population structure provided by
the Korean Statistical Information Service [6, 17]. Health-
care costs were measured in Korean Won (KRW) and
converted to United States Dollars (USD) using the aver-
age 2017 exchange rate (1 USD = 1130.84 KRW).
Statistical analysis
We compared baseline characteristics, including demo-
graphic and clinical characteristics, annual healthcare re-
source utilization, and annual healthcare costs between
the exudative AMD and non-AMD groups. Continuous
variables were tested using the paired t-test, while cat-
egorical variables were tested with McNemar’s test.
As most cost data has a positively skewed distribution,
it is difficult to obtain unbiased and precise estimates of
incremental costs by calculating mean differences or
running a simple ordinary least squares (OLS) [18]. His-
torically, an OLS for log-scale or a generalized linear
model (GLM) with log links analysis can be used to ad-
dress observed skewed distribution in the analysis. To
choose the type of model, we examined the kurtosis and
heteroscedasticity of the residuals from the log-scale
analysis, according to a previously developed algorithm
[18]. Given that the log-scale residuals were both lepto-
kurtic and heteroscedastic, following two models were
compared to assess the incremental cost of exudative
AMD group compared with non-AMD group: (1) OLS
with a log transformation and heteroscedastic retransfor-
mation and (2) GLM with a log link function and
gamma distribution. We adjusted for age group (5-year
interval), sex, type of insurance, residence, disability, CCI
score, and baseline healthcare resource utilization in
both models. For the heteroscedastic retransformation, a
variance function was estimated for the independent var-
iables suspected of causing heteroscedasticity, such as
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age group, type of insurance, CCI score, and baseline
healthcare resource utilization [19].
SAS version 9.4 (SAS Institute Inc., Cary, NC, USA)
and STATA SE 14.0 was used for statistical analysis.
Institutional Review Board (IRB)/Ethics Committee ap-
proval was obtained by the Seoul National University
Bundang Hospital (X-1710-429-907) and the study com-
plied with the guidelines of the Declaration of Helsinki.
Results
A total of 7119 individuals were identified as incident
exudative AMD patients who met the eligibility criteria;
these were matched to 7119 individuals who constituted
the non-AMD group (Fig. 1). The exudative AMD and
non-AMD matching-candidates differed significantly in
most of their baseline characteristics (Additional file 1:
Table S1). However, after propensity score-based match-
ing, baseline characteristics between the exudative AMD
and non-AMD groups were well-balanced in terms of
standardized differences and P-values (Table 1). The c-
statistic of the propensity score model was 0.663.
Figure 2a shows that the exudative AMD group had a
greater number of outpatient visits relative to the non-
AMD group (mean 39.01 vs. 31.18; P-value < 0.0001), while
the total length of hospitalization was shorter in the exuda-
tive AMD group (mean 1.96 days vs. 4.93 days; P-value <
0.0001) during the follow-up period. Ophthalmology costs,
especially AMD treatment costs, greatly contributed to the
total healthcare costs in the exudative AMD group (Fig. 2b).
As noted earlier, cost data were highly skewed in both
groups.
Results of the OLS analysis showed that the total
healthcare cost was 2.13 times higher in the exudative
AMD group relative to the non-AMD group (95% confi-
dence interval [CI]; 2.08–2.17) (Table 2).
The GLM analysis showed that the total healthcare
cost was 4.06 times (the exponential of 1.40) higher in
the exudative AMD group relative to the non-AMD
group (95% CI 3.82–4.31). After retransformation, the
annual incremental total cost per patient with exudative
AMD was estimated as $5519 using the OLS model and
$3699 using the GLM model, which were greater than
the observed differences (Table 3).
The estimated total burden of exudative AMD in the
Korean population was $368,063,007 in 2014 ($3699
[the annual healthcare cost per patient, estimated via
GLM]) * (99,503 [projected number of Korean adults
aged 40 or over having exudative AMD]).
Discussion
This study found that patients with exudative AMD had sig-
nificantly higher medical costs in comparison to carefully-
Fig. 1 Sample selection flow. AMD, age-related macular degeneration; DB, database; NHIS, National Health Insurance Service. aCandidates for the
non-AMD group were preliminarily matched to the exudative AMD group in a 1:10 to 1:20 ratio by age group and date of healthcare facility visits
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matched non-AMD reference group in the era of anti-VEGF
treatment. Understandably, treatment costs related to exuda-
tive AMD contributes the majority of the total healthcare
costs in the exudative AMD group and, however, incremen-
tal ophthalmology-related cost observed in the exudative
AMD group was partly compensated by incremental non-
ophthalmology-related cost in the non-AMD group.
Two studies reported the cost of exudative AMD be-
fore the era of anti-VEGF treatment. Cruess et al. re-
ported that the annual incremental cost of a patient with
Table 1 Baseline charateristics of study population after propensity score matching
Characteristic Exudative AMD group (n = 7119) Non-AMD group
(n = 7119)
P-value Standardized difference (%)
Male, No. (%) 4099 (57.58) 4134 (58.07) 0.41 −0.99
Age, No. (%), years
< 45 10 (0.14) 7 (0.10) 0.59 1.16
45–49 65 (0.91) 65 (0.91) 0.00
50–54 438 (6.15) 442 (6.21) −0.25
55–59 761 (10.69) 746 (10.48) 0.68
60–64 1092 (15.34) 1122 (15.76) −1.16
65–69 1334 (18.74) 1377 (19.34) −1.53
70–74 1428 (20.06) 1376 (19.33) 1.84
75–79 1110 (15.59) 1104 (15.51) 0.22
80–84 607 (8.53) 620 (8.71) −0.64
≥ 85 274 (3.85) 260 (3.65) 1.05
Income level, No. (%)a
0 277 (3.89) 256 (3.60) 0.66 1.53
1 562 (7.89) 555 (7.80) 0.33
2 445 (6.25) 433 (6.08) 1.25
3 421 (5.91) 419 (5.89) 0.71
4 420 (5.90) 456 (6.41) 0.08
5 466 (6.55) 493 (6.93) −2.12
6 545 (7.66) 547 (7.68) −1.52
7 640 (8.99) 624 (8.77) −0.08
8 750 (10.54) 744 (10.45) 0.77
9 1074 (15.09) 1109 (15.58) 0.29
10 1519 (21.34) 1483 (20.83) −1.36
Insurance, No. (%)
NHI program 6842 (96.11) 6863 (96.40) 0.54 −1.53
Medical aid program 277 (3.89) 256 (3.60) 1.53
Residence, No. (%)
Seoul (Capital city) 1649 (23.16) 1611 (22.63) 0.79 1.26
Metropolitan city 1738 (24.41) 1720 (24.16) 0.58
Others 3732 (52.42) 3788 (53.21) −1.58
Charlson comorbidity index, mean (SD) 0.59 (0.58) 0.59 (0.56) 0.96 0.00
Length of hospitalization during the
baseline period, mean (SD), days
2.41 (14.62) 2.64 (13.94) 0.22 −1.47
Number of outpatient visits during the
baseline period, mean (SD)
30.96 (28.22) 30.97 (28.39) 0.98 −0.02
Number of emergency department visits
during the baseline period, mean (SD)
0.09 (0.46) 0.10 (0.40) 0.76 −0.32
AMD age-related macular degeneration, NHI National Health Insurance, SD standard deviation
aIncome was categorized according to the insurance contribution. Level 10 denotes the highest insurance contribution (i.e. the highest income) and level 1
denotes the lowest insurance contribution (i.e. the lowest income) within NHI program. Level 0 denotes individuals covered by Medical aid program
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Fig. 2 a Descriptive analysis of annual healthcare resource utilization during a 1-year follow-up period. b Descriptive analysis of annual healthcare
costs during a 1-year follow-up period. AMD, age-related macular degeneration; USD, United States Dollar
Table 2 Results of econometric models of healthcare costs associated with exudative AMD
Variables Ordinary least square Generalized linear model
Beta (95% CI) P-value Beta (95% CI) P-value
AMD 2.13 (2.08 to 2.17) < 0.001 1.40 (1.34 to 1.46) < 0.001
Age group −0.02 (− 0.03 to − 0.00) 0.016 0.06 (0.04 to 0.07) < 0.001
Sex 0.13 (0.09 to 0.18) < 0.001 0.05 (−0.01 to 0.11) 0.102
Insurance 0.01 (−0.04 to 0.05) 0.769 0.05 (−0.01 to 0.10) 0.097
Residence −0.00 (− 0.03 to 0.02) 0.908 0.00 (− 0.03 to 0.04) 0.805
Disability 0.13 (0.06 to 0.20) < 0.001 0.25 (0.17 to 0.34) < 0.001
Charlson comorbidity index 0.22 (0.18 to 0.27) < 0.001 0.21 (0.15 to 0.26) < 0.001
Length of hospitalization 0.01 (0.01 to 0.01) < 0.001 0.01 (0.01 to 0.01) < 0.001
Number of outpatient visits 0.01 (0.01 to 0.02) < 0.001 0.01 (0.01 to 0.01) < 0.001
Number of ED visits 0.02 (−0.03 to 0.08) 0.426 0.05 (− 0.02 to 0.12) 0.179
AMD age-related macular degeneration, CI confidence interval, ED emergency department
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bilateral exudative AMD relative to a control subject
ranged from €2965 to €7887 (equivalent to $3347 to
$8902 in reference to the average 2017 exchange rate) in
2005 using the prospective data collected in five coun-
tries [9]. Similar to our study, they presented that
patients suffering exudative AMD had higher vision-
related costs and lower non-vision-related costs than
controls. In addition, Bonastre et al. also estimated that
the annual costs of AMD management in four European
countries ranged from €10,816 to €13,073 in 2001 [20].
In this study, cost of photodynamic therapy accounted
for 84–94% of total cost of AMD management. Despite
treatment strategies in these studies did not hold any-
more in the era of anti-VEGF treatment, they endorsed
the heavy burden of exudative AMD even before the
paradigm shift of exudative AMD treatment.
In Korea, Jeong et al. previously estimated the annual
costs per patient associated with exudative AMD to be
$10,246 in 2014, which is 2–3 times higher than our
estimates [7]. The difference may be largely due to the
change in reimbursement criteria on the maximum
number of ranibizumab injections allowable per year. In
January 2013, the annual maximum number of injections
was expanded from 5 injections per eye to 10 injections
per patient. Thereafter, 14 injections per patient started
being covered in November 2014. Considering our ana-
lysis was based on the data between 2010 and 2013
whereas Jeong et al. used the data in 2014, the estimated
number of ranibizumab injections per patient might be
larger in Jeong et al. compared with our study. In fact,
Jeong et al. reported that 77% of patients received ranibi-
zumab more than 4 times a year and 35% of patients re-
ceived ranibizumab more than 10 times a year. In other
retrospective studies which used Korean hospital data be-
tween September 2009 and January 2014, a similar analysis
period with our study, the average number of ranibizumab
injections were reported as 4.0–4.5 per year [21, 22].
Considering that the general population also pays
healthcare costs according to their own health needs,
measuring costs without appropriate controls may exag-
gerate the true burden of the disease. By defining the
control as the non-healthy population, with a similar
severity of comorbidities to the patients with exudative
AMD, we adopted a conservative approach in measuring
the burden of exudative AMD. Moreover, we did not in-
clude uninsured treatments, which may have led to an
underestimation of the burden of exudative AMD. In
fact, optical coherence tomography (OCT) is one of the
most important tests performed to assess pharmaco-
logical response and disease progress in patients with ex-
udative AMD, but it was not insured until 2015 in Korea
and was not considered in our analysis. Generally, OCT
is performed at every AMD-related visit in Korea, cost-
ing about $50–$150 for each service.
In most circumstances, cost data has some or all of
the following properties: (1) nonnegative outcomes; (2) a
nontrivial fraction of zero outcomes; and (3) positively
skewed outcomes [18]. If there is a substantial fraction
of zero outcomes, a two-part model or sample selection
model can be used to address the zero mass problem
[23]. In this study, there was no significant impact from
zero mass problems because only 0.58% of study popula-
tion had zero costs for total healthcare costs. Therefore,
we did not use a two-part model or sample selection
model, although we did add 1 KRW to all cost data to
enable log transformations. According to the previously
developed algorithm [18], we compared the results from
the OLS analysis with log transformation followed by
heteroscedastic retransformation and GLM analysis with
a log link function and gamma distribution in terms of
their performance. We found that there were some
difficulties in the estimation of a variance function for
heteroscedastic retransformation in the OLS analysis. Al-
though we identified independent variables suspected of
causing heteroscedasticity, there was a possibility that some
unmeasured confounders existed and resulted in a residual
bias in the estimation of the variance function. Contrary to
the OLS analysis, the GLM analysis had no retransforma-
tion issue because it could directly provide the expected
mean by exponentiation without estimating the variance
function. For this reason, we concluded that GLM analysis
might provide more precise estimates than OLS.
To our knowledge, this is the first study to explore the
incremental economic burden of exudative AMD group
Table 3 Annual incremental healthcare costs associated with exudative AMD in USD
Costs Observed differences Ordinary least square Generalized linear model
Total costs + 2880 + 5519 + 3699
Pre-diagnosis costs + 50 + 79 + 56
AMD treatment costs + 3078 N/Aa N/Aa
Ophthalmology costs + 2988 + 7419 + 3010
Non-ophthalmology costs −288 + 42 −39
AMD, age-related macular degeneration; N/A, not applicable; USD, United States Dollar
aNot applicable because AMD treatment costs are totally zero in non-AMD group
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relative to a non-AMD reference group using a nation-
wide database. We tried to minimize the effect of
confounders by comparing the exudative AMD and
non-AMD groups, which had similar distributions of
baseline covariates after being matched by propensity
score. Moreover, we used a previously developed algo-
rithm to enable more elaborate methodology for cost
analysis, addressing the widespread problem of skewed
distributions in medical expenditure studies.
A high economic burden of disease could be a threat
to sustainability of healthcare system. Therefore, under-
standing the costs of disease is necessary to justify and
prioritize healthcare policies, and can help decision
makers find out an efficient way of allocating the limited
resources. In this respect, this study may provide further
evidence for the costs and resource utilization related
with exudative AMD, which could be used for assessing
impact of healthcare policies and cost-effectiveness of
certain interventions.
Several limitations of this study should be considered.
Since we used claims data, uninsured examinations (e.g.
OCT and fundus indocyanine green angiography), the
use of treatments for an unapproved indication, or over-
the-counter agents were not included in the cost ana-
lysis. These facts might have led to an underestimation
of exudative AMD treatment costs and the incremental
total costs of exudative AMD. Further, exudative AMD
was defined based on diagnosis and ranibizumab codes,
which may not have been specific enough to prevent any
misclassifications in the study population. However,
given that most patients are treated with ranibizumab
once they are diagnosed with exudative AMD, this mis-
classification issue is likely to be negligible. Since ranibi-
zumab began to be covered in 2009, the reimbursement
criteria have changed to increase the maximum number
of ranibizumab injections allowable per year. While this
change may affect the utilization pattern of ranibizumab,
we were unable to address this detail in this study. Further
studies are warranted to explore the economic burden of
exudative AMD in relation to change in reimbursement
criteria by using more recent data. Finally, exudative
AMD can cause an economic burden beyond medical
costs. Therefore, non-medical costs, such as productivity
loss, should be explored in future studies.
Conclusions
Exudative AMD was associated with significantly in-
creased healthcare costs relative to those of a non-AMD
group with similar demographic and clinical characteris-
tics. A GLM analysis showed that patients with exudative
AMD are estimated to cost an additional $3699 annually.
Since the prevalence of exudative AMD is expected to
grow continuously, policy actions are needed to manage
the socioeconomic burden of exudative AMD.
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